MedTrace Logo

Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use

NCT00430573 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-05-17

Study results available
· View outcomes & findings →

Summary

This study examines whether isolated doses of d-cycloserine enhance the efficacy of an exposure-based cognitive-behavioral treatment for chronic and treatment refractory substance dependence.

Conditions

  • Substance-Related Disorders

Interventions

DRUG

D-cycloserine

Single dosage of D-cycloserine is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)

DRUG

Placebo

Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Massachusetts General Hospital

    collaborator OTHER

  • Boston University Charles River Campus

    lead OTHER

Principal Investigators

  • Michael W. Otto, Ph.D. · Boston University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-06-30
Completion
2009-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430573 on ClinicalTrials.gov